Please login to the form below
Meda appoints Maria Carell regional director for the US
She joins the Swedish speciality pharma company with management experience from Novartis, Actavis and Q-Med
Swedish speciality pharma company Meda has appointed Maria Carell to a senior management position at its US operations.
She has sat on the firm's board for almost a year and will now take up the role of regional director for the US as Meda waits for a decision from the Food and Drug Administration (FDA) on its rhinitis treatment Dymista.
The US regulator is due to decide in early May on Dymista (azelastine hydrochloride and fluticasone propionate), a nasal spray formulation for patients 12 years and older with seasonal allergic rhinitis.
"Maria Carell will be an important addition to the team that prepares the launch of Dymista in the US", said Anders Lönner, Meda's CEO.
She joins Meda with extensive experience in the health care sector, including management positions at Novartis, generics company Actavis and medical device firm Q-Med.
Following Carell's appointment to the US regional role she has declined re-election to Meda's board.
Share
Related Hub content
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
